Can I read Real-World Analysis of Teclistamab in 123 RRMM Patients From Germany on EtoBox?
Real-World Analysis of Teclistamab in 123 RRMM Patients From Germany by wyk18775 is a document available to read on EtoBox.
What is Real-World Analysis of Teclistamab in 123 RRMM Patients From Germany about?
A real-world analysis of teclistamab in 123 patients with relapsed and refractory multiple myeloma (RRMM) in Germany showed an overall response rate of 59.3% and a median progression-free survival of 8.7 months. The study highlighted lower response rates in patients with extramedullary disease and those pretreated with idecabtagene vicleucel (ide-cel). Despite these challenges, teclistamab demonstrated comparable efficacy and safety to the pivotal MAJESTEC-1 trial outcomes.
- Author
- wyk18775
- Language
- EN